Stone et al. found that clinical doses of DNA methyltransferase inhibitors (DNMTi), and histone deacetylase inhibitors (HDACi) on ID8-Defb29/Vegf-a (ID8-VEGF-Defensin) tumor-bearing mice, decreased immunosuppression within the TME by enhancing type I IFN signaling and alleviating PD-1 blockage [185]. This evidence concerns the gene VEGFA and neoplasm.